ClinicalTrials.gg
RecruitingNCT07589634TRI ProUpdated Nov 3, 2026

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

A Phase 2 interventional study of Ramantamig and Tocilizumab in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Recruiting at 60 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 3, 2026First sites in 6 new countriesStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 126 studies in Multiple Myeloma by Johnson & Johnson — 13 open to participants now, 33 under way, 12 of them phase 3. Multiple Myeloma · Johnson & Johnson.

Planned enrollment
28th of 100
230 · median 125
Started
2026
with 5 others
Phase 2
32 of 126
4 open now
Primary completion
2027-12
later than 19 of 32 live
Registered
124th of 126
by date

Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 28th largest by planned enrollment of the 100 interventional ones that give a count, is one of 6 that started in 2026, is one of 32 in phase 2, reaches primary completion later than 19 of the 32 other live ones, and was the 124th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

13 of the 126 studies in Multiple Myeloma by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Multiple Myeloma by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an acute inflammatory reaction that can occur during treatment and may be associated with flu-like or other systemic symptoms, such as fever and tiredness.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of multiple myeloma (MM) as defined by the criteria: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria; b. at screening as assessed by local laboratory as defined in the protocol
  • Received at least 1 prior lines of antimyeloma therapy
  • disease as defined: a. Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease (PD) by the IMWG response criteria greater than (>) 60 days after cessation of treatment.; b. Refractory disease is defined as failure to achieve a response or confirmed PD by the IMWG response criteria during previous treatment or less than or equal to (\<=) 60 days after cessation of treatment
  • Have an (ECOG) performance status (PS) score of 0 to 2 at screening and immediately before the start of study treatment administration. Participants with ECOG PS 2 or 3 are eligible for the study if the ECOG PS score is related to stable physical limitations (example, wheelchair-bound due to prior spinal cord injury) and not related to MM or associated therapy
  • Have clinical laboratory values meeting the criteria specified in the protocol

Exclusion criteria

Exclusion criteria:

  • Concurrent use of any other anticancer treatment (including non-palliative radiotherapy) or agent
  • Major surgery, (for example, requiring general anesthesia) within 2 weeks before first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study
  • Suspected or known allergies, , or intolerance to ramantamig and tocilizumab or their
  • Presence of any of the following: a. Any ongoing myelodysplastic syndrome or B-cell (other than MM); b. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; c. Any active malignancy other than MM
  • Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    Arm A: Tocilizumab + Ramantamig

    Participants will receive tocilizumab along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until progressive disease (PD) or intolerable toxicity (whichever is earlier).

    Drug: Ramantamig · Drug: Tocilizumab

  • Placebo comparator
    Arm B: Placebo + Ramantamig

    Participants will receive placebo (saline) along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until PD or intolerable toxicity (whichever is earlier).

    Drug: Ramantamig · Drug: Placebo

Interventions

  • Ramantamig will be administered as subcutaneous (SC) injection.

    Also known as: JNJ-79635322

  • Tocilizumab will be administered as intravenous (IV) injection.

  • DrugPlacebo

    Placebo (saline) will be administered as IV injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS)

    Percentage of participants alive and free of treatment-emergent ASTCT Grade \>=2 CRS without the use of intervening treatment for CRS of any grade by the end of day 28 from first ramantamig dose will be reported.

    Time frame: By the end of Day 28 from first ramantamig dose

Secondary outcomes

  1. Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the End of Day 28 from First Ramantamig Dose

    Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade \>=2, and Grade \>=3 by the end of day 28 from first ramantamig dose, respectively, will be reported.

    Time frame: By the end of Day 28 from first ramantamig dose

  2. Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 During Ramantamig Treatment

    Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade \>=2, and Grade \>=3 during ramantamig treatment will be reported.

    Time frame: Up to 38 months

  3. Percentage of Participants with Re-occurrence of CRS with ASTCT Grade >=2 After the Initial Occurrence of Treatment-Emergent Grade >=2 CRS Event

    Percentage of participants with re-occurrence of CRS with ASTCT Grade \>=2 after the initial occurrence of treatment-emergent Grade \>=2 CRS event will be reported.

    Time frame: Up to 38 months

  4. Percentage of Participants with Re-occurrence of CRS for All Grades

    Percentage of participants with re-occurrence of CRS for all Grades will be reported.

    Time frame: Up to 38 months

  5. Overall Response

    Overall response is defined as the percentage of participants who achieve partial response (PR) or better prior to progressive disease (PD) or subsequent antimyeloma therapy, in accordance with the international myeloma working group (IMWG) criteria.

    Time frame: Up to 38 months

  6. Complete Response (CR) or Better

    CR or better rate is defined as the percentage of participants achieving CR or stringent complete response (sCR) prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria.

    Time frame: Up to 38 months

  7. Very Good Partial Response (VGPR) or Better

    VGPR or better rate is defined as the percentage of participants achieving VGPR, CR or sCR prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria.

    Time frame: Up to Month 38

  8. Duration of Response (DoR)

    DoR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of PD according to the IMWG response criteria or death due to any cause, whichever occurs first.

    Time frame: Up to 38 months

  9. Time to Response (TTR)

    TTR is defined as the time from the date of randomization to the date of first documentation of a confirmed response (PR or better) for participants who have PR or better as their best response.

    Time frame: Up to 38 months

  10. Progression-Free Survival (PFS)

    PFS is defined as the duration from the date of randomization to either PD or death, whichever comes first. Disease progression will be determined according to the IMWG response criteria.

    Time frame: Up to Month 38

  11. Time to Subsequent Antimyeloma Therapy

    Time to subsequent antimyeloma therapy is defined as the time from randomization to the start of subsequent antimyeloma treatment. Death due to progressive disease without the start of any subsequent antimyeloma therapy will be considered as an event.

    Time frame: Up to Month 38

  12. Percentage of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. Any new or worsening AE occurring at or after the initial administration of study treatment through the day of last dose plus 30 days or prior to the start of subsequent antimyeloma therapy, whichever is earlier, or any follow-up AE (linked to an existing TEAE) with onset date and time beyond 30 days after the last dose of study treatment but prior to the start of subsequent therapy, or any AE that is considered treatment-related regardless of the start date of the event, is considered to be treatment-emergent. TEAEs will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 6.0. Severity scale ranges from Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, Grade 5= death related to adverse event.

    Time frame: Up to 38 months

  13. Percentage of Participants with Abnormalities in Laboratory Parameters

    Percentage of participants with abnormalities in laboratory parameters (serum chemistry and hematology) will be reported.

    Time frame: Up to 38 months

  14. Percentage of Participants with Incidence of Adverse Events of Clinical Interests

    Percentage of participants with incidence of adverse events of clinical interests such as cytopenia will be reported.

    Time frame: Up to 38 Months

07

Study locations

60 of 60 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.jnj.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's planned 18 months is below that.

Counting every sponsor, half of 504 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

Completion moved once since we started tracking on Sep 25, 2026: Nov 2030 → Jul 2030, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 15, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jul 30, 2030was Nov 2030
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
51 sites added — first sites in France, Greece, Portugal, Spain, Sweden and 1 more
All 6 countries

France, Greece, Portugal, Spain, Sweden, Hungary

Show 51 added (8 United States, 7 Greece, 7 Spain, 6 France, 6 Portugal, 5 Sweden, 5 Hungary, 4 Australia, 2 Argentina, 1 Malaysia)
  • City of Hope Phoenix · Goodyear, United States
  • City of Hope Orange County Lennar Foundation Cancer Center · Irvine, United States
  • Colorado Blood Cancer Institute · Denver, United States
  • Washington University School Of Medicine · St Louis, United States
  • Hospital Italiano de Buenos Aires · Buenos Aires, Argentina
  • Wollongong Hospital · Wollongong, Australia
  • Centre Hospitalier Victor Dupouy · Argenteuil, France
  • Centre Hospitalier de la Cote Basque · Bayonne, France
  • Centre de Cancerologie de la Sarthe · Le Mans, France
  • CHU Nantes - Hotel Dieu · Nantes, France
  • Uni General Hospital of Alexandroupolis · Alexandroupoli, Greece
  • 251 Air Force General Hospital · Athens, Greece
  • Alexandra General Hospital of Athens · Athens, Greece
  • General University Hospital of Patras · Rio, Greece
  • Theageneio Cancer Hospital · Thessaloniki, Greece
  • Hippokration Hospital · Thessaloniki, Greece
  • Hospital Pulau Pinang · George Town, Malaysia
  • Uls Braga - Hosp. Braga · Braga, Portugal
  • Hosp. Cuf Descobertas · Lisbon, Portugal
  • Uls Santo Antonio - Hosp. Santo Antonio · Porto, Portugal
  • Uls Sao Joao - Hosp. Sao Joao · Porto, Portugal
  • Hosp. Univ. La Paz · Madrid, Spain
  • Hosp. de Navarra · Pamplona, Spain
  • Hosp. Univ. Dr. Peset · Valencia, Spain
  • Falu Lasarett Medicinkliniken Falun · Falun, Sweden
  • Sahlgrenska Universitetssjukhuset · Gothenburg, Sweden
  • Skanes universitetssjukhus · Lund, Sweden
  • Karolinska University Hospital Huddinge · Stockholm, Sweden
  • Akademiska Sjukhuset · Uppsala, Sweden
  • Stanford University Medical Center · Palo Alto, United States
  • …and 21 more on the registry record
across 2 updates, Oct 1, 2026 – Nov 3, 2026
Study completion
Nov 8, 2030→Jul 30, 2030
Nov 3, 2026
Eligibility
2 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedRelapsed or refractory disease as defined: a. Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease (PD) by the IMWG response criteria greater than (>) 60 days after cessation of treatment.; b. Refractory disease is defined as failure to achieve a response (that is, partial response or better) or confirmed PD by the IMWG response criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment
  • EditedHave clinical laboratory values meeting the criteria specified in the protocol during the screening and within 1 day of the start of administration of study treatment
Exclusion criteria
  • EditedPresence of any of the following: a. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); b. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; c. Any active malignancy other than MM that is considered at high risk of recurrence requiring systemic therapy
Oct 1, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time framePercentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS)End of Day 28 from ramantamig dose → By the end of Day 28 from first ramantamig dose
  • DescriptionPercentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS): how it is measured was reworded
Oct 1, 2026
Secondary outcomes
2 edited, 11 time frame changed, 1 added, 4 removed
What changed in the outcomes
  • EditedPercentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the End of Day 28 from First Ramantamig DoseTime frame: End of Day 28 from ramantamig dose → By the end of Day 28 from first ramantamig dose
  • EditedOverall Response Rate (ORR)Time frame: Up to approximately 3 years and 6 months → Up to 38 months
  • AddedTime to Subsequent Antimyeloma TherapyTime frame: Up to Month 38
  • RemovedTime To Next Line of Therapy (TTNT)Time frame: Up to approximately 3 years and 6 months
  • RemovedTime to the First Treatment-emergent Infection with Toxicity Grade >=3Time frame: Up to approximately 3 years and 6 months
  • RemovedPercentage of Participants with Primary Immunoglobulin Replacement Therapy (IgRT) Prophylaxis UseTime frame: Up to approximately 3 years and 6 months
  • RemovedPercentage of Participants with Secondary IgRT Prophylaxis Use or Without IgRT Prophylaxis UseTime frame: Up to approximately 3 years and 6 months
  • Time framePercentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 During Ramantamig TreatmentUp to 37 months → Up to 38 months
  • Time framePercentage of Participants with Re-occurrence of CRS with ASTCT Grade >=2 After the Initial Occurrence of Treatment-Emergent Grade >=2 CRS EventUp to approximately 3 years and 6 months → Up to 38 months
  • Time framePercentage of Participants with Re-occurrence of CRS for All GradesUp to approximately 3 years and 6 months → Up to 38 months
  • Time frameComplete Response (CR) or BetterUp to approximately 3 years and 6 months → Up to 38 months
  • Time frameVery Good Partial Response (VGPR) or BetterUp to approximately 3 years and 6 months → Up to Month 38
  • Time frameDuration of Response (DoR)Up to approximately 3 years and 6 months → Up to 38 months
  • Time frameTime to Response (TTR)Up to approximately 3 years and 6 months → Up to 38 months
  • Time frameProgression-Free Survival (PFS)Up to approximately 3 years and 6 months → Up to Month 38
  • Time framePercentage of Participants With Treatment-Emergent Adverse Event (TEAE) by SeverityUp to approximately 3 years and 6 months → Up to 38 months
  • Time framePercentage of Participants with Abnormalities in Laboratory ParametersUp to approximately 3 years and 6 months → Up to 38 months
  • Time framePercentage of Participants with Incidence of Adverse Events of Clinical InterestsUp to approximately 3 years and 6 months → Up to 38 Months
Oct 1, 2026
Show all 2 updates
  1. Nov 3, 2026
    22 sites added — first site in Hungary
    Show 22 added (5 Hungary, 4 United States, 4 Spain, 3 Australia, 2 France, 2 Portugal, 1 Argentina, 1 Greece)
    • Stanford University Medical Center · Palo Alto, United States
    • Ohio Health Research Institute · Columbus, United States
    • Sarah Cannon Research Institute · Nashville, United States
    • University of Utah Huntsman Cancer Institute · Salt Lake City, United States
    • Hospital Universitario Austral · Pilar, Argentina
    • Flinders Medical Centre · Bedford Park, Australia
    • Sunshine Coast University Hospital · Birtinya, Australia
    • St Vincents Hospital Melbourne · Fitzroy, Australia
    • CHU de Grenoble · La Tronche, France
    • Centre Hospitalier de Quimper Cornouaille · Quimper, France
    • Metaxa Cancer Center Hospital Of Piraeus · Piraeus, Greece
    • Semmelweis Egyetem · Budapest, Hungary
    • Del Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet Szent Laszlo Telephely · Budapest, Hungary
    • Orszagos Onkologiai Intezet · Budapest, Hungary
    • Pecsi Tudomanyegyetem Klinikai Kozpont · Pécs, Hungary
    • Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar · Szeged, Hungary
    • Ipo Lisboa · Lisbon, Portugal
    • Uls Gaia Espinho · Vila Nova de Gaia, Portugal
    • Hosp. de La Santa Creu I Sant Pau · Barcelona, Spain
    • Hosp. de Leon · León, Spain
    • Hosp. Blua Sanitas Valdebebas · Madrid, Spain
    • Hosp Regional Univ de Malaga · Málaga, Spain
    Study completion Nov 8, 2030→Jul 30, 2030
    + 1 other change: verification date
  2. Oct 1, 2026
    29 sites added — first sites in France, Greece, Portugal, Spain and Sweden
    Show 29 added (6 Greece, 5 Sweden, 4 United States, 4 France, 4 Portugal, 3 Spain, 1 Argentina, 1 Australia, 1 Malaysia)
    • City of Hope Phoenix · Goodyear, United States
    • City of Hope Orange County Lennar Foundation Cancer Center · Irvine, United States
    • Colorado Blood Cancer Institute · Denver, United States
    • Washington University School Of Medicine · St Louis, United States
    • Hospital Italiano de Buenos Aires · Buenos Aires, Argentina
    • Wollongong Hospital · Wollongong, Australia
    • Centre Hospitalier Victor Dupouy · Argenteuil, France
    • Centre Hospitalier de la Cote Basque · Bayonne, France
    • Centre de Cancerologie de la Sarthe · Le Mans, France
    • CHU Nantes - Hotel Dieu · Nantes, France
    • Uni General Hospital of Alexandroupolis · Alexandroupoli, Greece
    • 251 Air Force General Hospital · Athens, Greece
    • Alexandra General Hospital of Athens · Athens, Greece
    • General University Hospital of Patras · Rio, Greece
    • Theageneio Cancer Hospital · Thessaloniki, Greece
    • Hippokration Hospital · Thessaloniki, Greece
    • Hospital Pulau Pinang · George Town, Malaysia
    • Uls Braga - Hosp. Braga · Braga, Portugal
    • Hosp. Cuf Descobertas · Lisbon, Portugal
    • Uls Santo Antonio - Hosp. Santo Antonio · Porto, Portugal
    • Uls Sao Joao - Hosp. Sao Joao · Porto, Portugal
    • Hosp. Univ. La Paz · Madrid, Spain
    • Hosp. de Navarra · Pamplona, Spain
    • Hosp. Univ. Dr. Peset · Valencia, Spain
    • Falu Lasarett Medicinkliniken Falun · Falun, Sweden
    • Sahlgrenska Universitetssjukhuset · Gothenburg, Sweden
    • Skanes universitetssjukhus · Lund, Sweden
    • Karolinska University Hospital Huddinge · Stockholm, Sweden
    • Akademiska Sjukhuset · Uppsala, Sweden
    Eligibility 2 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedRelapsed or refractory disease as defined: a. Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease (PD) by the IMWG response criteria greater than (>) 60 days after cessation of treatment.; b. Refractory disease is defined as failure to achieve a response (that is, partial response or better) or confirmed PD by the IMWG response criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment
    • EditedHave clinical laboratory values meeting the criteria specified in the protocol during the screening and within 1 day of the start of administration of study treatment
    Exclusion criteria
    • EditedPresence of any of the following: a. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); b. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; c. Any active malignancy other than MM that is considered at high risk of recurrence requiring systemic therapy
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time framePercentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS)End of Day 28 from ramantamig dose → By the end of Day 28 from first ramantamig dose
    • DescriptionPercentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS): how it is measured was reworded
    Secondary outcomes 2 edited, 11 time frame changed, 1 added, 4 removed
    What changed in the outcomes
    • EditedPercentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the End of Day 28 from First Ramantamig DoseTime frame: End of Day 28 from ramantamig dose → By the end of Day 28 from first ramantamig dose
    • EditedOverall Response Rate (ORR)Time frame: Up to approximately 3 years and 6 months → Up to 38 months
    • AddedTime to Subsequent Antimyeloma TherapyTime frame: Up to Month 38
    • RemovedTime To Next Line of Therapy (TTNT)Time frame: Up to approximately 3 years and 6 months
    • RemovedTime to the First Treatment-emergent Infection with Toxicity Grade >=3Time frame: Up to approximately 3 years and 6 months
    • RemovedPercentage of Participants with Primary Immunoglobulin Replacement Therapy (IgRT) Prophylaxis UseTime frame: Up to approximately 3 years and 6 months
    • RemovedPercentage of Participants with Secondary IgRT Prophylaxis Use or Without IgRT Prophylaxis UseTime frame: Up to approximately 3 years and 6 months
    • Time framePercentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 During Ramantamig TreatmentUp to 37 months → Up to 38 months
    • Time framePercentage of Participants with Re-occurrence of CRS with ASTCT Grade >=2 After the Initial Occurrence of Treatment-Emergent Grade >=2 CRS EventUp to approximately 3 years and 6 months → Up to 38 months
    • Time framePercentage of Participants with Re-occurrence of CRS for All GradesUp to approximately 3 years and 6 months → Up to 38 months
    • Time frameComplete Response (CR) or BetterUp to approximately 3 years and 6 months → Up to 38 months
    • Time frameVery Good Partial Response (VGPR) or BetterUp to approximately 3 years and 6 months → Up to Month 38
    • Time frameDuration of Response (DoR)Up to approximately 3 years and 6 months → Up to 38 months
    • Time frameTime to Response (TTR)Up to approximately 3 years and 6 months → Up to 38 months
    • Time frameProgression-Free Survival (PFS)Up to approximately 3 years and 6 months → Up to Month 38
    • Time framePercentage of Participants With Treatment-Emergent Adverse Event (TEAE) by SeverityUp to approximately 3 years and 6 months → Up to 38 months
    • Time framePercentage of Participants with Abnormalities in Laboratory ParametersUp to approximately 3 years and 6 months → Up to 38 months
    • Time framePercentage of Participants with Incidence of Adverse Events of Clinical InterestsUp to approximately 3 years and 6 months → Up to 38 Months
    + 3 other changes: identifiers, verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07589634
Responsible party
Sponsor
First posted
May 15, 2026
Start date
Jun 30, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Jul 30, 2030 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion